NEW YORK, January 6, 2026, 12:28 EST — Regular session
- Moderna shares rise about 11% as BofA lifts its price objective on the stock
- Company has filed for approvals of its mRNA-1010 seasonal flu vaccine in major markets
- Investors look to Jan. 9 U.S. payrolls data and a Jan. 12 conference appearance for the next catalysts
Shares of Moderna Inc (MRNA.O) were up 10.7% at $35.60 in midday trading on Tuesday after BofA Global Research raised its price objective on the vaccine maker. The stock touched a session high of $36.25. 1
The jump comes as investors weigh whether Moderna can turn its mRNA platform into steadier, seasonal revenue after the post-pandemic drop in COVID-19 vaccine demand. Traders have been sensitive to shifts in sell-side views as the company leans on new product launches and tighter spending to narrow losses.
On Monday, Moderna said it filed for marketing authorization — regulatory clearance to sell — in the United States, Europe, Canada and Australia for its investigational seasonal influenza vaccine, mRNA-1010, aimed at adults 50 and older. CEO Stéphane Bancel said mRNA’s “agility and flexibility” could help vaccines “more closely match evolving strains.” Moderna said a Phase 3 study showed a 26.6% relative vaccine efficacy, or rVE — a measure of how much better a shot performed versus a comparator vaccine — against a standard-dose flu vaccine. 2
In a shareholder letter released the same day, Bancel said Moderna beat its 2025 cash-cost reduction commitment by nearly $1 billion and projected 2026 cash costs of about $4.2 billion as it works toward cash breakeven in 2028. Moderna also said its next-generation COVID-19 shot mNEXSPIKE accounted for about 24% of U.S. retail COVID vaccinations in 2025. 3
A filing showed Moderna furnished the shareholder letter in a Form 8-K under Regulation FD, a U.S. rule designed to stop companies from selectively disclosing market-moving information to a subset of investors. 4
But BofA analyst Tim Anderson, who raised his target to $24 from $21 while keeping an underperform rating, said Moderna has done “a solid job” cutting costs and expects the shares to keep trading on COVID uptake and sentiment, with headwinds unlikely to ease into the 2026/2027 season. 5
